BESREMI MPEN Trademark

Trademark Overview

On Monday, September 9, 2024, a trademark application was filed for BESREMI MPEN with the United States Patent and Trademark Office. The USPTO has given the BESREMI MPEN trademark a serial number of 98739871. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Saturday, March 22, 2025. This trademark is owned by PHARMAESSENTIA CORPORATION. The BESREMI MPEN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations contained in pen injectors for treatment of Polycythemia vera; Pharmaceutical preparations, namely, ropeginterferon alfa-2b, contained in injectors for treatment of viral infections, cancers, polycythemia vera, essential thrombocythemia, myelofibrosis, and/or other myeloproliferative neoplasms; Pharmaceutical preparations contained in injectors for treatment of myeloproliferative neoplasms; Pharmaceutical preparations contained in pen injectors for treatment of myeloproliferative neoplasms; Pharmaceutical preparations, namely, ropeginterferon alfa-2b, contained in pen injectors for treatment of viral infections, cancers, polycythemia vera, essential thrombocythemia, myelofibrosis, and/or other myeloproliferative neoplasms; Pharmaceutical preparations contained in injectors for treatment of Polycythemia vera
besremi mpen

General Information

Serial Number98739871
Word MarkBESREMI MPEN
Filing DateMonday, September 9, 2024
Status680 - APPROVED FOR PUBLICATION
Status DateSaturday, March 22, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations contained in pen injectors for treatment of Polycythemia vera; Pharmaceutical preparations, namely, ropeginterferon alfa-2b, contained in injectors for treatment of viral infections, cancers, polycythemia vera, essential thrombocythemia, myelofibrosis, and/or other myeloproliferative neoplasms; Pharmaceutical preparations contained in injectors for treatment of myeloproliferative neoplasms; Pharmaceutical preparations contained in pen injectors for treatment of myeloproliferative neoplasms; Pharmaceutical preparations, namely, ropeginterferon alfa-2b, contained in pen injectors for treatment of viral infections, cancers, polycythemia vera, essential thrombocythemia, myelofibrosis, and/or other myeloproliferative neoplasms; Pharmaceutical preparations contained in injectors for treatment of Polycythemia vera

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 9, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePHARMAESSENTIA CORPORATION
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTaipei City 115 115603
TW

Trademark Events

Event DateEvent Description
Monday, September 9, 2024NEW APPLICATION ENTERED
Monday, September 9, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 9, 2024APPLICATION FILING RECEIPT MAILED
Tuesday, March 11, 2025ASSIGNED TO EXAMINER
Friday, March 21, 2025NON-FINAL ACTION E-MAILED
Friday, March 21, 2025NON-FINAL ACTION WRITTEN
Friday, March 21, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 22, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, March 22, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 22, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 22, 2025APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords

mpen besremi pharmaceutical treatment injectors preparations contained myeloproliferative neoplasms vera polycythemia thrombocythemia